Name | Value |
---|---|
NAME | VA-PNEUMOCOCCAL IMMUNIZATION PPSV23 |
PRINT NAME | Pneumococcal PPSV23 (Pneumovax) |
CLASS | NATIONAL |
SPONSOR | VA NATIONAL CENTER FOR HEALTH PROMOTION AND DISEASE PREVENTION (NCP) |
USAGE | CR |
EDIT HISTORY |
|
DESCRIPTION | Updated guidelines Fall 2014 - patients age 65 and older should received anatomic asplenia, CSF leaks, or cochlear implants, and who have not previously received PCV13 or PPSV23, should receive a dose of PCV13 first, followed by a dose of PPSV23 at least 8 weeks later if <age 65 or immunocompromised and at least 1 year later if 65 or older AND not immunocompromised. Subsequent doses of PPSV23 should follow current PPSV23 recommendations for adults at high risk. Specifically, a second PPSV23 dose is recommended 5 years after the first PPSV23 dose for persons aged 19-64 years with functional or anatomic asplenia and for persons with immunocompromising one dose of PCV13, if possible, this dose should be given prior to conditions. Additionally, those who received PPSV23 before age 65 years for any indication should receive another dose of the vaccine at age 65 years, or later if at least 5 years have elapsed since their previous PPSV23 dose. Previous vaccination with PPSV23. Adults aged >=19 years with immunocompromising conditions, functional or anatomic asplenia, CSF leaks, or cochlear implants, who previously have received >=1 doses of PPSV23 should be given a PCV13 dose >=1 year after the last PPSV23 dose was received. For those who require additional doses of PPSV23, the first PPSV23. Persons vaccinated with PCV13 prior to age 65 do not need a such dose should be given no sooner than 8 weeks after PCV13 for ages <65 or if immunocompromised, no sooner than 1 year after PCV13 for ages 65 and older, not immunocompromised and at least 5 years after the most recent dose of PPSV23. Pneumococcal polysaccharide (PPSV) vaccination - Vaccinate all persons with the following indications: Medical: Chronic lung disease (including asthma); chronic cardiovascular diseases; diabetes mellitus; chronic liver diseases; cirrhosis; chronic second dose after age 65 (this applies to PCV13 only and not to PPSV23). alcoholism; functional or anatomic asplenia (e.g., sickle cell disease or splenectomy [if elective splenectomy is planned, vaccinate at least 2 weeks before surgery]); immunocompromising conditions (including chronic renal failure or nephrotic syndrome); and cochlear implants and cerebrospinal fluid leaks. Vaccinate as close to HIV diagnosis as possible. Other: Residents of nursing homes or long-term care facilities and persons who smoke cigarettes. Routine use of PPSV is not recommended for American Indians/Alaska Natives or persons aged less than 65 years unless they have underlying medical conditions that are PPSV indications. However, public health authorities may consider recommending PPSV for American Indians/Alaska Natives and persons aged 50 through 64 years who are living in areas where the risk for invasive pneumococcal disease is increased. Revaccination with PPSV23 One-time revaccination after 5 years is recommended for persons aged 19 through 64 years with chronic renal failure or nephrotic syndrome; functional or anatomic asplenia (e.g., sickle cell disease or Updated guidelines October 2012 splenectomy); and for persons with immunocompromising conditions. For persons aged 65 years and older, one-time revaccination is recommended with PPSV23 if they were vaccinated 5 or more years previously and were aged less than 65 years at the time of primary vaccination. Pneumococcal vaccine-nave persons. ACIP recommends that adults aged 19 years of age and older with immunocompromising conditions, functional or |
FINDINGS |
|
FUNCTION FINDINGS |
|
TECHNICAL DESCRIPTION | Fall 2014 - add age >=65 as indication for PCV13. Adjust this reminder disease) which compares the date of birth to the date of administration of PCV13. The DTIME_DIFF function in FF(22) and FF(23) compares the date of the most recent dose to today's date. FF(22) (((DTIME_DIFF(7,1,"DATE",19,1,"DATE","D","A")>55)&(FI(17)! (DIFF_DATE(19,1)<23742)))!(DTIME_DIFF(7,1,"DATE",19,1,"DATE","D","A")>364) &FI(19))!(FI(15)&'FI(19)) PCV13 >55 days ago if administered <65 or immunocompromised, Chemo=CH : taxonomy and drugs PCV13 over 1 year ago, or contraindication to PCV13 and has not had PCV13 FF(23) ((DTIME_DIFF(7,1,"DATE",19,1,"DATE","D","A")>55)&FI(19))!'FI(19) PCV13 over 56 days ago, Or has not had PCV13 (since this FF is used only on patients <65, it does not need to LTS=Long term steroids explicitly include an age like FF(22) does) The cohort logic is divided into 2 sections - 1. for patients who need PCV13 first and 2. for patients who do not need PCV13. 1. (((FI(3)&FF(12))!FI(4)!FI(7)!FI(18)!(FI(16)&(FF(16)!FF(17)!FF(18)!FF(19))) )&FF(22)) 2. !(((FI(2)&FF(13)&FF(23)))&'((FI(3)&FF(12))!FI(4)!FI(7)!FI(18)!(FI(16)&(FF( 16)!FF(17)!FF(18)!FF(19)))))&'FI(8) Part 1 will not be true if unless PCV13 was given outside the required time periods (2M for <65 or IC, 1Y for >64 not IC), so PCV13 must be given and the time period must have elapsed or the patient has a contraindication and then FF(22) will be true. Part 2 will not be true if PCV13 was administered in the past 2 months, this part of the logic only applies to patients less than 65 who do not require PCV13. Cohort: 1. (IC or HstR or CH or LTS) and either already got PCV13 but not in the past 8 weeks or has contraindication to PCV13 2. Other dx or age>64 and not IC/HstR/CH/LTS or has contraindication to PCV13 to be due after that dose is given. Baseline frequencies 1. >65 99Y 2. IC 5Y 3. HstR 99Y 4. HR 99Y 5. LTS 5Y 6. CH 5Y Function Findings Frequency Rank 1 <age 65 and 2 or more doses*: 99Y 1 2 >age 64 and 1 dose after age 64: 99Y 1 3 no dose >64, IC/CH/LTS and no 2nd dose 5Y 2 8 >age 64, IC/CH/LTS, has PCV13, no dose>64 5Y 2 2 >age 64 and 1 dose after age 64: 99Y 1 4 >age 64,dosed <65, no dose>64, not IC/CH 5Y 2 PPSV23 6 (HR or Other dx) not IC/CH and <age 65: 99Y 3 *2 doses are counted only if given more than 1460 days apart (4Y) or one is marked as a booster dose. For IC/CH/LTS: FF 1,2,3,8 FF3 above can be explained this way - Patient is IC and has had a dose before age 65, needs a second dose 5 years later. FF(3) is true and the reminder is due 5Y after the recorded dose. If that second dose is given, then FF(1) takes over and the reminder is resolved (99Y). If the patient turns 65, then FF(8) is true and the reminder is due again 5Y after the last dose. Once that dose after age 65 is given, then FF(2) takes over and the reminder is resolved (99Y). IC: immunocompromised (HIV, renal failure, nephrotic syndrome, splenic For no IC/CH/LTS Baseline dose due for HR and HstR, FF6 sets for patients <age 65 who are not IC/CH/LTS. Once they turn 65, then FF4 is applicable and the reminder is due 5 years after the prior dose. Once a dose is given after age 65, then FF2 is applicable and any dose after age 65 will resolve. Resolution: PPSV23 or deferral or an order dysfx, etc. FF5 provides a message about the need for an additional dose after age 65 if the patient's most recent dose was prior to age 65 for non-IC/CH/LTS patients. FF7 provides a message about the need for an additional dose after age 65 for IC/CH/LTS patients who have already gotten PCV13. FF10 assesses the last 2 doses of pneumococcal vaccine to be sure that Highest Risk= HstR: cochlear implant, CSF leak they were more than 4 years apart FF16, 17, 18 and 19 look at finding 16 and evaluate to see if it is an ICD code, an outpatient drug or a non-intravitreal administration of a chemotherapy drug. FF20 provides a message if PCV13 is needed. This is just in case someone looks at this reminder to see why it is NOT due. High Risk=HR - Other Diagnoses: (cardiac, pulmonary, smoking, liver Update June 2015 - ACIP changes recommendations to increase time period from PCV13 to PPSV23 to one year for patients age 65 and older who are not immunocompromised. Remains 8 weeks for patients <65 or who are immunocompromised. Two new function findings are added: FF(22) and FF(23) The time period for waiting ((2M for <65 or IC, 1Y for >64 and not IC) is based on the age of the patient at the time of the vaccine administration. In FF(22) this is represented by the DIFF_DATE function |
CUSTOMIZED COHORT LOGIC | (((FI(3)&FF(12))!FI(4)!FI(7)!FI(18)!(FI(16)&(FF(16)!FF(17)!FF(18)!FF(19))))&FF(22))!(((FI(2)&FF(13)&FF(23)))&'((FI(3)&FF(12))!FI(4)!FI(7)!FI(18)!(FI(16)&(FF(16)!FF(17)!FF(18)!FF(19)))))&'FI(8) |
INTERNAL PATIENT COHORT LOGIC | (((FI(3)&FF(12))!FI(4)!FI(7)!FI(18)!(FI(16)&(FF(16)!FF(17)!FF(18)!FF(19))))&FF(22))!(((FI(2)&FF(13)&FF(23)))&'((FI(3)&FF(12))!FI(4)!FI(7)!FI(18)!(FI(16)&(FF(16)!FF(17)!FF(18)!FF(19)))))&'FI(8) |
PATIENT COHORT FINDINGS COUNT | 25 |
PATIENT COHORT FINDINGS LIST | 3;FF12;4;7;18;16;FF16;FF17;FF18;FF19;FF22;2;FF13;FF23;3;FF12;4;7;18;16;FF16;FF17;FF18;FF19;8 |
CUSTOMIZED RESOLUTION LOGIC | FI(5)!FI(6)!FI(14) |
INTERNAL RESOLUTION LOGIC | FI(5)!FI(6)!FI(14) |
RESOLUTION FINDINGS COUNT | 3 |
RESOLUTION FINDINGS LIST | 5;6;14 |
AGE FINDINGS COUNT | 11 |
AGE FINDINGS LIST | 2;3;4;16;18;FF1;FF2;FF3;FF4;FF6;FF8 |
INFORMATION FINDINGS COUNT | 12 |
INFORMATION FINDINGS LIST | 1;9;12;13;15;17;19;FF10;FF20;FF21;FF5;FF7 |
WEB SITES |
|
# OF GEN. COHORT FOUND LINES | 0 |
# GEN. COHORT NOT FOUND LINES | 0 |
# GEN. RES. FOUND LINES | 0 |
# GEN. RES. NOT FOUND LINES | 0 |
BASELINE AGE FINDINGS |
|
# SUM. COHORT FOUND LINES | 0 |
# SUM. COHORT NOT FOUND LINES | 0 |
# SUM. RES. FOUND LINES | 0 |
# SUM. RES. NOT FOUND LINES | 0 |